Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

244.50 -3.88 (-1.56%)
Streaming Delayed Price Updated: 3:58 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Insulet Corporation
Via Business Wire
Goldman Sachs Reveals Winning Portfolio: 'Rule of 10' Unlocks S&P 500's Future Top Performers
Via Benzinga
Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions
From Insulet Corporation
Via Business Wire
Expert Ratings for Insulet
Via Benzinga
Insulet Earnings Perspective: Return On Capital Employed
Via Benzinga
Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom
From Insulet Corporation
Via Business Wire
Medtronic's EOflow Acquisition Will Not Impact Insulet's Omnipod' Insulin Pump In Near or Medium Term: Analyst
Via Benzinga
AMD Stock, AI Play And New S&P 500 Member Lead 5 Stocks Near Buy Points
AMD and a new S&P 500 member lead this weekend's watch list. 
Via Investor's Business Daily
Insulet Reports Better-Than-Expected Q1 Earnings As Omnipod 5 Launch Gains Momentum, Lifts Guidance
  
Via Benzinga
Recap: Insulet Q1 Earnings
Via Benzinga
4 Analysts Have This to Say About Insulet
Via Benzinga
Analyst Expectations for Insulet's Future
Via Benzinga
Preview: Insulet's Earnings
Via Benzinga
Insulet Announces New Organizational Structure to Drive Further Growth
From Insulet Corporation
Via Business Wire
Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment
From Insulet Corporation
Via Business Wire
Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes
From Insulet Corporation
Via Business Wire
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
Medical stocks are holding up amid economic and market uncertainty. 
Via Investor's Business Daily
Insulet to Announce First Quarter 2023 Financial Results on May 4, 2023
From Insulet Corporation
Via Business Wire
CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (24% constant currency)
From Insulet Corporation
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
From Insulet Corporation
Via Business Wire
3 Growth Stocks That Have Delivered 10X Returns Over the Past Decade
Are these stocks still good buys today? 
Via The Motley Fool
Insulet Acquires Assets of Automated Glucose Control LLC (AGC)
From Insulet Corporation
Via Business Wire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery Technologies
From Insulet Corporation
Via Business Wire
The 7 Best Tech Stocks to Buy for February 2023
Some of the best tech stocks are looking increasingly attractive as the worst fears fail to materialize. Here are seven to consider. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Insulet Has Potential To Gain More Than Analysts Are Forecasting
Even as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range. 
Via MarketBeat
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.